GlassScriptPhysician profile
Ara J Hanissian
NPI 1679649271
$25,968.95
in general payments reported to CMS, 2019-2025
67 companies · $4,064 in 2025
The $4,064 reported for 2025 was more than what 98% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,167 · 2020: $3,443 · 2021: $4,060 · 2022: $2,268 · 2023: $3,796 · 2024: $4,170 · 2025: $4,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,030.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,670.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,809.28 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,781.42 | 2019-2025 | |
| Lilly USA, LLC | $2,233.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,410.68 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $1,184.11 | 2019-2025 | Trintellix, Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $954.03 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $833.11 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $759.19 | 2021-2025 | |
| Glaxosmithkline, LLC. | $696.22 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $665.60 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Amarin Pharma, INC. | $659.55 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $653.89 | 2019-2021 | |
| Abbott Laboratories | $584.69 | 2022-2025 | Freestyle Libre 3 |
| Bausch Health US, LLC | $468.04 | 2020-2025 | Aplenzin |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ara Hanissian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.